Sotorasib provides durable clinical benefit for patients with non-small cell lung cancer and KRAS mutations
Post-overdose outreach programs in Massachusetts expanding
28 January 2021‘Honey, I’m home’: Pandemic life for married couples can lead to sadness, anger
28 January 2021Sotorasib provides durable clinical benefit for patients with non-small cell lung cancer and KRAS mutations
In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating CodeBreak 100’s phase I results, according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
